BACKGROUND AND PURPOSE: Intermedin is a member of the calcitonin gene-related-peptide (CGRP) family expressed in endothelial cells and acts via calcitonin receptor-like receptors (CLRs). Here we have analysed the receptors for intermedin and its effect on the endothelial barrier in monolayers of human umbilical vein endothelial cells (HUVECs). EXPERIMENTAL APPROACH: We analysed the effect of intermedin on albumin permeability, contractile machinery, actin cytoskeleton and VE-cadherin in cultured HUVECs. KEY RESULTS: Intermedin concentration-dependently reduced basal endothelial permeability to albumin and antagonized thrombin-induced hyperpermeability. Intermedin was less potent (EC(50) 1.29 ± 0.12 nM) than adrenomedullin (EC(50) 0.24 ± 0.07 nM) in reducing endothelial permeability. These intermedin effects were inhibited by AM(22-52) and higher concentrations of αCGRP(8-37), with pA(2) values of αCGRP(8-37) of 6.4 for both intermedin and adrenomedullin. PCR data showed that HUVEC expressed only the CLR/RAMP2 receptor complex. Intermedin activated cAMP/PKA and cAMP/Epac signalling pathways. Intermedin's effect on permeability was blocked by inhibition of PKA but not of eNOS. Intermedin antagonized thrombin-induced contractile activation, RhoA activation and stress fibre formation. It also induced Rac1 activation, enhanced cell-cell adhesion and antagonized thrombin-induced loss of cell-cell adhesion. Treatment with a specific inhibitor of Rac1 prevented intermedin-mediated barrier stabilization. CONCLUSION AND IMPLICATIONS: Intermedin stabilized endothelial barriers in HUVEC monolayers via CLR/RAMP2 receptors. These effects were mediated via cAMP-mediated inactivation of contractility and strengthening of cell-cell adhesion. These findings identify intermedin as a barrier stabilizing agent and suggest intermedin as a potential treatment for vascular leakage in inflammatory conditions.
BACKGROUND AND PURPOSE:Intermedin is a member of the calcitonin gene-related-peptide (CGRP) family expressed in endothelial cells and acts via calcitonin receptor-like receptors (CLRs). Here we have analysed the receptors for intermedin and its effect on the endothelial barrier in monolayers of human umbilical vein endothelial cells (HUVECs). EXPERIMENTAL APPROACH: We analysed the effect of intermedin on albumin permeability, contractile machinery, actin cytoskeleton and VE-cadherin in cultured HUVECs. KEY RESULTS:Intermedin concentration-dependently reduced basal endothelial permeability to albumin and antagonized thrombin-induced hyperpermeability. Intermedin was less potent (EC(50) 1.29 ± 0.12 nM) than adrenomedullin (EC(50) 0.24 ± 0.07 nM) in reducing endothelial permeability. These intermedin effects were inhibited by AM(22-52) and higher concentrations of αCGRP(8-37), with pA(2) values of αCGRP(8-37) of 6.4 for both intermedin and adrenomedullin. PCR data showed that HUVEC expressed only the CLR/RAMP2 receptor complex. Intermedin activated cAMP/PKA and cAMP/Epac signalling pathways. Intermedin's effect on permeability was blocked by inhibition of PKA but not of eNOS. Intermedin antagonized thrombin-induced contractile activation, RhoA activation and stress fibre formation. It also induced Rac1 activation, enhanced cell-cell adhesion and antagonized thrombin-induced loss of cell-cell adhesion. Treatment with a specific inhibitor of Rac1 prevented intermedin-mediated barrier stabilization. CONCLUSION AND IMPLICATIONS: Intermedin stabilized endothelial barriers in HUVEC monolayers via CLR/RAMP2 receptors. These effects were mediated via cAMP-mediated inactivation of contractility and strengthening of cell-cell adhesion. These findings identify intermedin as a barrier stabilizing agent and suggest intermedin as a potential treatment for vascular leakage in inflammatory conditions.
Authors: David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord Journal: Pharmacol Rev Date: 2002-06 Impact factor: 25.468
Authors: Muhammad Aslam; Frauke V Härtel; Muhammad Arshad; Dursun Gündüz; Yaser Abdallah; Heinrich Sauer; Hans Michael Piper; Thomas Noll Journal: Cardiovasc Res Date: 2010-03-03 Impact factor: 10.787
Authors: Stefan Hippenstiel; Martin Witzenrath; Bernd Schmeck; Andreas Hocke; Mathias Krisp; Matthias Krüll; Joachim Seybold; Werner Seeger; Wolfgang Rascher; Hartwig Schütte; Norbert Suttorp Journal: Circ Res Date: 2002-10-04 Impact factor: 17.367
Authors: Uwe Pfeil; Muhammad Aslam; Renate Paddenberg; Karin Quanz; Chia L Chang; Jae-Il Park; Barbara Gries; Amir Rafiq; Petra Faulhammer; Anna Goldenberg; Tamara Papadakis; Thomas Noll; Sheau Y T Hsu; Norbert Weissmann; Wolfgang Kummer Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-08-14 Impact factor: 5.464
Authors: Euan Parnell; Brian O Smith; Timothy M Palmer; Anna Terrin; Manuela Zaccolo; Stephen J Yarwood Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: Michael Schnoor; Alexander García Ponce; Eduardo Vadillo; Rosana Pelayo; Jan Rossaint; Alexander Zarbock Journal: Cell Mol Life Sci Date: 2017-02-02 Impact factor: 9.261
Authors: Pavel I Nedvetsky; Xiaocheng Zhao; Thomas Mathivet; Irene M Aspalter; Fabio Stanchi; Ross J Metzger; Keith E Mostov; Holger Gerhardt Journal: Development Date: 2016-10-01 Impact factor: 6.868
Authors: Holger Christian Müller-Redetzky; Wolfgang Kummer; Uwe Pfeil; Katharina Hellwig; Daniel Will; Renate Paddenberg; Christoph Tabeling; Stefan Hippenstiel; Norbert Suttorp; Martin Witzenrath Journal: PLoS One Date: 2012-05-01 Impact factor: 3.240